Processa Pharmaceuticals Schedules Conference Call to Discuss Third Quarter Results and Provide Drug Development Update on November 11 at 5:30 p.m. EST
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) will report its financial results for Q3 2021 on November 11, 2021. The company plans to hold a conference call at 5:30 PM ET on the same day to discuss its financial performance and business highlights. Processa focuses on developing treatments for patients with unmet medical needs, with active programs targeting metastatic colorectal and breast cancer, as well as conditions like ulcerative necrobiosis lipoidica and GI motility disorders. The company emphasizes efficient development to meet critical milestones.
- Upcoming financial results expected on November 11, 2021, could indicate progress.
- Active clinical pipeline includes promising programs for serious conditions.
- None.
HANOVER, MD, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, today announced that the Company will report financial results for the quarter ended September 30, 2021 on Thursday November 11, 2021.
The Company will host a conference call at 5:30 p.m. Eastern Time on Thursday November 11, 2021 to discuss its financial results and business highlights.
Conference Call Information
To participate in this event, please log-on or dial-in approximately 5-10 minutes before the beginning of the call.
Date: November 11, 2021
Time: 5:30 PM
Toll-Free: 1-855-327-6838 Toll / International: 1-604-235-2082 Conference ID: 10016982
The conference call will also be available via a live, listen-only webcast and can be accessed through the Investor Relations section of Processa Pharmaceuticals website at:https://processapharmaceuticals.com/
Please follow the Company on LinkedIn and at Twitter@ProcessaPharma.
About Processa Pharmaceuticals, Inc.
The mission of Processa is to develop products with existing clinical evidence of efficacy for patients with unmet or underserved medical conditions who need treatment options that improve survival and/or quality of life. The Company uses these criteria for selection to further develop its pipeline programs to achieve high-value milestones effectively and efficiently. Active clinical pipeline programs include: PCS6422 (metastatic colorectal cancer and breast cancer), PCS499 (ulcerative necrobiosis lipoidica) and PCS12852 (GI motility/gastroparesis). The members of the Processa development team have been involved with more than 30 drug approvals by the FDA (including drug products targeted to orphan disease conditions) and more than 100 FDA meetings throughout their careers. For more information, visit the company’s website at www.processapharma.com.
Forward-Looking Statements
This release contains forward-looking statements. The statements in this press release that are not purely historical are forward-looking statements which involve risks and uncertainties. Actual future performance outcomes and results may differ materially from those expressed in forward-looking statements. Please refer to the registration statement relating to the securities being sold in this offering, which identifies important risk factors which could cause actual results to differ from those contained in the forward-looking statements.
For More Information:
Michael Floyd
mfloyd@processapharma.com
301-651-4256
Jason Assad
Investor Relations
Jassad@processapharma.com
678-570-6791
FAQ
When will Processa Pharmaceuticals report its Q3 2021 financial results?
What time is the Processa Pharmaceuticals conference call?
What is the focus of Processa Pharmaceuticals' drug development?
What are the clinical programs Processa Pharmaceuticals is currently pursuing?
